Previous medical history 206
Seventy percent of patients were diagnosed by a pediatric gastroenterologist and just more 207 than half in a university center. In the 3 m before diagnosis, 23% took antibiotics, 23% 208 suffered from an infectious episode of which 40% were labeled a GI infection. Twenty-three 209 % experienced a major stressful event (i.e. defined as being stressful for the patient by the 210 patient himself, his parents and the physician) and 42% had past surgery, of which ear-nose-211 throat surgery in 45% and inguinal hernia correction and circumcision in 15%. Disease related 212 surgery was reported in 17%, consisting of abscess drainages and surgical fistula treatment. 213
Eight patients had previous appendectomy (7%). In previously and newly diagnosed patients 214 24% and 7% respectively had disease related surgery prior to diagnosis. With this exception, 215 no significant differences were found in the medical history of the previously and newly 216 diagnosed patients. 217
Immunization data were available from 248 patients. Polio was recorded in 222 patients 218 (86%). Fifty three patients received vaccines in addition to the national recommendations 13 , 219 including hepatitis A, yellow fever, influenza and typhoid. Six patients were vaccinated for 220 varicella. 221
Passive smoking was present in 16% of patients, active smoking in 1%. 222
Family history 223
A positive family history for IBD in first degree relatives occurred in 29 patients (11.4%). CD 224 was mentioned in 25 patients, ulcerative colitis in 4. Both conditions were mutually exclusive. 225
Auto-immune pathology, including psoriasis, lupus, diabetes type I and celiac disease affected 226 the broader family (parents, siblings, grandparents, cousins, aunts and uncles) of 35.9% of 227 patients. Family history was similar in previously and newly diagnosed patients. 228
Presentation 229
Belgian pediatric CD patients presented at a median age of 12.5 y (range 1.6 -18.0 y) after a 230 median duration of symptoms of 3 m (range 1-12 m). Median symptom duration prior to 231 diagnosis did not differ in patients with a positive family history. Symptoms at diagnosis are 232 presented in Figure 1 . The main presenting symptoms were abdominal pain (84%), diarrhea 233 (72%) and weight loss or lack of weight gain (72%). 234
Of the 208 patients from whom data on height velocity was available, 29% presented with 235 faltering growth. Height z-scores and BMI z-scores were available from 240 patients. Median 236 z-score for height was -0.39 (range -5.35 to 12.71). Severe growth retardation (z-score < -237 2SD) affected 8.7% of the population. Median z-score for BMI was -1.04 (range -6.74 to 238 2.07). Sixty patients (25%) had a BMI z-score <= -2SD. The previously diagnosed group 239 belonged mostly to the age category >12 y whereas median and mean age were comparable 240 for previous and recent diagnoses. The previously diagnosed patients had lower z-scores for The Paris classification subdivides upper GI involvement in L4A (proximal to Treitz 253 ligament) and L4B (distal to Treitz ligament). These regions were involved in 144 (56%) and 254 83 (32%) patients respectively. Fourty eight patients had both L4A and L4B involvement. 255 Perianal disease, as described in the PCDAI, occurred in 28% of patients. Stricturing disease 256 was mentioned in 15 patients (5.8%) at diagnosis. Out of the 245 patients in whom extra 257 intestinal manifestations as defined by the PCDAI were recorded (erythema nodosum, 258 arthritis, uveitis, arthralgias, pyoderma gangrenosum), 72 scored positive (29%). Disease 259 severity was measured by PCDAI or PGA. The results are presented in Table 2 . Disease was 260 mild in 24%, moderate in 43% and severe in 28% of the cohort. Disease severity and disease 261 location were comparable in previously and newly diagnosed patients. 262 (Table 3) . 289
The analysis was carried out on the entire group for variables that did not differ in previously 290 and newly diagnosed patients. A separate analysis was performed for the differing variables in 291 order to avoid bias due to group heterogeneity. In the previously diagnosed group, follow-up 292 data obtained at registration in the database were also analyzed. 293
Neonatal variables such as birth weight, gestational age and mode of delivery revealed no 294 associations with age, disease location or disease severity at diagnosis. Breastfed children 295 were diagnosed at a younger age (p=0.0003) and tended to have more colonic disease (L2) 296 (p=0.013). No associations were found between medical history (antibiotic use, major 297 stressful events, surgery and/or infections prior to diagnosis) and disease location or severity 298 at diagnosis. Younger patients at diagnosis had more infectious episodes before diagnosis 299 (p=0.015) and received more frequently antibiotics as initial treatment (p= 0.002), as well as 300 steroids and 5 ASA (p=0.01; p=0.004). Their family history for IBD was more often positive 301 (p=0.032). Age at diagnosis was not associated with disease location when analyzing the 302 entire group but in the previously diagnosed, patients presenting with L3 tended to be older 303 (p=0.057). Height z-scores (p=0.004) and ileocolonic disease location (L3) (p=0.011) were 304 associated with more severe disease at diagnosis; patients with ileal (L1) (p= 0.013) disease 305 had less severe disease at diagnosis in univariate analysis. Nevertheless multiple regression 306 analysis withheld only CRP as independent predictive factor for disease severity. 307
In the total cohort, several disease related factors influenced the initial treatment choice. 308
Patients with moderate to severe disease and with L4 involvement were more likely to receive 309 steroids in combination therapy (p= 0.045 and p=0.048) and enteral therapy in combination 310 (p=0.005 and p=0.043) as initial management. Initial treatment with immunomodulator 311 monotherapy was associated with height z-score, disease severity, L1 and L4 location, but the 312 number of patients on this treatment was extremely limited (4 patients) as were patients on 313 antibiotic monotherapy (4 patients). Patients with L1 involvement had more often antibiotic 314 combination therapy (p=0.032). 315
In newly diagnosed patients, steroids were less likely to be used in patients with perianal 316 disease (p=0.006) and patients with upper GI involvement (L4A) tended to be older 317 (p=0.047). Patients with lower z-scores for height were more likely to start enteral nutrition at 318 diagnosis (p=0.002). 319
320
Associations between variables at diagnosis and at inclusion for previously diagnosed 321 patients (Table 4) . 322
During the follow up of previously diagnosed patients, we noticed an important effect of the 323 disease duration on several factors. Patients with a longer disease course at inclusion were 324 diagnosed at a younger age (<0.001) and had better z-scores for height at diagnosis (p= 325 0.008). They were more likely to have had 5 ASA at diagnosis (p<0.001). An association was 326 found between the z-scores for height at diagnosis and BMI z-scores at inclusion (p=0.025) 327 with weight as interfering factor indicating a better weight gain over time compared to 328 growth. Patients with concomitant conditions at diagnosis had a better height z-score at 329 inclusion (p=0.001). 330
At the time of inclusion, patients with mild disease were more likely to have had steroids at 331 diagnosis (p=0.004; OR=3.8 (95%CI 1.7-8.4). Patients with L3 had less severe disease at 332 inclusion (p=0.02; OR 2.8-95%CI 1.1-7.4), in contrast to patients with L1 who received less 333 steroids (p=0.03; OR 0.3 -95%CI 0.1-0.9). Need for surgery was only influenced by disease 334 behavior (S) (p=0.001; OR 6.8 -95% CI 1.8-25.3) not by disease severity, location or other 335 treatment modalities. No further significant associations were found between disease related 336 elements such as disease severity or disease location and initial treatment, but a positive 337 family history for IBD was associated with the use of 5-ASA at diagnosis (OR 2.1 95% CI 338 1.07-4.49), and 5-ASA and immunomodulators during follow up (p=0.02; OR 2.5-95%CI 339 1.1-4.3 and p=0.004; OR 2.7 -95%CI 1.3-5.5). 340
There was a decrease in the use of steroids and 5-ASA (p= 0.001; OR 0.02 -95%CI 0.002-0.3; 341 p=0.001; OR 0.03 -0.004-0.3) and an increase in prescriptions of immunomodulators (p=0.03; 342 OR 1.8-95%CI 0.08-41.1) over time, paralleling a decrease in disease severity (p=0.01) 343 (Table 5 ). The decrease in disease severity can be reflected by the decrease in perianal disease 344 and extra-intestinal manifestations between diagnosis and inclusion in the database, 345 respectively 28% vs 7.2% and 29% vs 10.5%. The association between immunomodulator 346 monotherapy at diagnosis and a better height z-score at inclusion is based on too few patients 347 (4 patients). pediatric GI centers caring for pediatric IBD patients participated in the study, it is impossible 354 to evaluate the exact number of pediatric patients treated by adult gastroenterologists. It is 355 however improbable that adult gastroenterologist would treat patients below the age of 16 y. 356
Therefore the incidence or prevalence rate presented here is but an approximation but the best 357 one possible. A better alternative would be a centralized national registry based on health 358 insurance data. 359
Based on BELCRO data, the estimated incidence of CD in Belgian children was 2.2/100 000 360 children <18y/y. This number compares with previous reports from France and Holland 11, 12 , 361 whereas incidence increases to 4.9/100000/y in Sweden 14 and 7/100 000/y in Finland 15 . 362
There is a clear North-South gradient with a higher prevalence in Northern countries 1 . The 363 median age of disease onset in BELCRO patients is comparable to what is found in 364 surrounding countries 3, 11, 12, [14] [15] [16] [17] [18] [19] . In contrast to the adult population, the majority of pediatric 365 patients are male. Female preponderance started to show from age 15 y on. Median duration 366 of symptoms prior to diagnosis was 3 m, which is shorter than in surrounding countries 18 . A 367 possible explanation is that specialized medical care is easily accessible in Belgium, 368 professional referral is not mandatory, travel distances are short and waiting lists are usually 369 short or non-existent. Health insurance is offered to all citizens. There are no public 370 campaigns, thus general awareness of CD is probably comparable to surrounding countries. 371
The majority of patients were Caucasian, including immigrants from North Africa and Turkey 372 for whom no subset was made. 373
Neonatal history and previous medical history did not neither influence disease severity nor 374 disease location in this cohort. Younger age at diagnosis was associated with breastfeeding 375 and an infectious episode prior to diagnosis. Seventy eight percent of BELCRO patients have 376 been (partially/exclusively) breastfed in the neonatal period. These results compare to 71% of 377 mothers starting breastfeeding in the general population 20 . The association between 378 breastfeeding and young age at diagnosis, found in our cohort, differs from the protective 379 effect suggested by other, limited data on the subject in pediatric IBD 21 . The relevance of the 380 correlation between breastfeeding and L2 remains to be confirmed. The breastfed group was 381 heterogeneous and recall bias is often a problem in studies recording breastfeeding 22 . 382 Therefore these data should be interpreted with extreme caution. In almost a quarter of 383 children, an infectious episode was noted in the 3 m before diagnosis of which 40% was 384 labeled a GI infection. Most of them belonged to the younger age category at diagnosis. This 385 association is not surprising, as younger children are more prone to infections in general. 386
Vaccination data indicate good adherence to the vaccination scheme of the American 387
Academy of Pediatrics also recommended by the Belgian authorities 13 . Only Polio 388 vaccination is mandatory. General vaccination coverage is known to be over 80% because all 389 recommended vaccinations are offered free of charge in special pediatric clinics 13, 23 . For CD 390 patients additional vaccinations were recently recommended to prevent opportunistic 391 infections [24] [25] [26] . Adherence to these recommendations is very low so far. We note that even 392 though national vaccination coverage is excellent, the information is often not recorded in the 393 medical files or not transferred when patients make a transition to adult care. Clearly, more 394 attention is needed in documenting and updating vaccination status at diagnosis knowing the 395 risk of opportunistic infections in this patient group due to the immunosuppressive medication 396 as part of their usual treatment. 397
Abdominal pain, diarrhea and weight loss were the predominant clinical symptoms as was 398 reported in literature 16, 18 . A BMI z-score below -1 was noticed in half of our pediatric 399 patients. The importance of growth failure as a presenting feature of CD still needs to be 400 emphasized. Early treatment and adequate nutrition are crucial for catch up growth and 401 achieving full height and weight potential. The previously diagnosed group demonstrates 402 symptom improvement following treatment and a decrease in growth failure. Height z-scores 403
were inversely correlated to disease severity meaning less severe disease improved growth, 404 reflected by better height z-scores. The relationship between BMI z-scores at inclusion and 405 height z-scores at diagnosis, imply in general an even better weight gain compared to growth 406 catch up. In the newly diagnosed population however, patients with lower z-scores were more 407 likely to receive enteral nutrition as part of the initial therapy indicating a recent, more 408 adequate therapeutic strategy for growth retardation at diagnosis. Certain data link growth 409 impairment to disease location 18 , this could not be confirmed in our cohort. The size of the 410 study population or the limited group of patients with severe growth retardation may influence 411 this result. 412 BELCRO confirmed that children with CD present with extensive and severe disease and with 413 high upper GI tract involvement. Details on the upper GI tract findings were not available at 414 this stage and it is possible that they were mainly not specific as involvement was based on 415 endoscopic and/or radiologic data. While evaluation of disease location for different age 416 categories, confirmed the finding of predominant colonic disease in the children under 6y of 417 age 3, 11, 16, 17 , it has to be stated that this was a very small group and the difference with ileal 418 and ileo-colonic disease is small. 419
The majority of patients had mild to moderate disease at diagnosis as evaluated by PCDAI 420 and PGA. Even though ileal and ileo-colonic disease seemed to be associated with disease 421 severity, multiple regression analysis only defined CRP as an independent risk factor for 422 disease severity. CRP is not part of the PCDAI as a reflection of disease severity but has 423 proven useful in several studies as a predictive factor for treatment response and to reflect 424 mucosal healing [27] [28] [29] . 425
Family IBD was more often found in young patients, possibly due to an earlier expression of 426 the disease in the genetically predisposed. Our data demonstrates the importance of adequate therapy at diagnosis as more severe initial 431 treatment results in less severe disease over time. Physicians in this cohort were definitely 432 compelled to use steroids in combination therapy as initial treatment for more severe disease. 433
After a mean follow up of 2.7 y for a subgroup, patients who presented with severe disease 434 were more likely to receive steroids as initial treatment and were also more likely to have 435 extensive disease (L3), while at inclusion, those patients appeared to be more controlled with 436 inactive PCDAI scores. The opposite is true for patients with isolated ileal disease. While 437 65.1% of patients at inclusion had received steroids as part of their previous treatment, only 438 11.6% were still on this treatment. These findings are markedly better than the American data 439
where, even though 61% of children showed a response to steroid treatment at 1 y, 31% 440 developed steroid dependency 31 . Another study showed a 40% relapse within 18 months after 441 discontinuation of this treatment 32 . Because of relapse rates, important side effects of steroid 442 treatment and to improve long term outcome, alternative maintenance therapy and even 443 induction therapy are investigated such as early immunomodulator use 32, 33 , enteral therapy 444 and in severe cases top down therapy with biologicals 34 . Enteral therapy, an effective 445 treatment in the pediatric CD population, induces remission, improves growth and leads to 446 mucosal healing [35] [36] [37] . Despite the safety of enteral therapy, our data demonstrate its very 447 limited use as an initial mono therapeutic approach. The way this treatment is introduced by 448 the medical team and the support to the patient and the parents determines its success. In the 449 newly diagnosed patients we notice its increased use for patients with growth retardation. In 450 this cohort disease location, disease behavior and age at diagnosis did not influence treatment 451 choice at diagnosis and disease outcome, except for patients with stricturing disease whom 452 had a greater need for surgery during follow up. 453
Immunomodulators were frequently prescribed, while biologicals only have a very limited 454 place at diagnosis.
Step down therapy was used as initial treatment in 2 patients because of the 455 extreme severe presentation of disease. A significant increase (p<0.001) in biological therapy 456 and immuunmodulators is noticed over time, reflecting the step up therapy generally used in 457 pediatrics. Today, except for the use of budesonide in mild to moderate ileal disease and the 458 use of biologicals in fistulizing disease 38 , therapeutic strategy is not influenced by disease 459 location or behavior even though we notice in our cohort that patients with extensive disease 460 tend to receive steroids more frequently at diagnosis and biologicals in combination therapy 461 during follow up. Physicians are less inclined to use biologicals in ileal disease in order to 462 avoid stricture formation. Recent American data compared the use of biologicals and 463 immunomodulators within the first 30 days after diagnosis in a diverse group of newly 464 diagnosed CD patients. No significant outcome differences were noted except that infliximab 465 treated children tended to be sicker at diagnosis 39 . The RISK study group looked 466 prospectively at the patients with deep ulcerations on colonoscopy at diagnosis. This was 467 associated with worse clinical parameters at diagnosis and worse disease severity scores 468 (PCDAI/PGA) at 1 y follow-up, more so for patients who lacked treatment with 469 immunomodulators or biologicals within 3 months after diagnosis 40 . These findings indicate 470 the possible important effect of adequate initial treatment on long term outcome data. 471
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